Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 28Head & Neck 4Other solid neoplasm 2Endocrine 2Thoracic 1Other hematologic neoplasm 1

Conditions

Differentiated Thyroid Cancer 2Nasopharyngeal Carcinoma 1Locally Advanced Thyroid Gland Carcinoma 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × donafenib × Head & Neck × Clear all
NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

West China Hospital

Phase 2 Recruiting
75 enrolled
Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT02698111 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated
204 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed
48 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡